Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity
- 28 April 2004
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 60 (4) , 237-246
- https://doi.org/10.1007/s00228-004-0762-z
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography–negative chemical ionization–mass spectrometryJournal of Chromatography B, 2004
- Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probeClinical Pharmacology & Therapeutics, 2000
- Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences*Clinical Pharmacology & Therapeutics, 1998
- The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin*Clinical Pharmacology & Therapeutics, 1998
- Rifampin reduces plasma concentrations and effects of zolpidem*Clinical Pharmacology & Therapeutics, 1997
- Concentrations and effects of zopiclone are greatly reduced by rifampicinBritish Journal of Clinical Pharmacology, 1997
- Triazolam is ineffective in patients taking rifampinClinical Pharmacology & Therapeutics, 1997
- Rifampin drastically reduces plasma concentrations and effects of oral midazolamPublished by Wiley ,1996
- Noninvasive tests of CYP3A enzymesPharmacogenetics, 1994
- Pencil and paper tests‐sensitivity to psychotropic drugs.British Journal of Clinical Pharmacology, 1984